These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 16462711

  • 1. Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy.
    Platis O, Anagnostopoulos G, Farmaki K, Posantzis M, Gotsis E, Tolis G.
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():279-81. PubMed ID: 16462711
    [Abstract] [Full Text] [Related]

  • 2. Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy.
    Christoforidis A, Perifanis V, Tsatra I, Vlachaki E, Athanassiou-Metaxa M.
    Diabetes Res Clin Pract; 2007 Apr; 76(1):6-11. PubMed ID: 16930760
    [Abstract] [Full Text] [Related]

  • 3. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
    Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G.
    Br J Haematol; 2006 Aug; 134(4):438-44. PubMed ID: 16822284
    [Abstract] [Full Text] [Related]

  • 4. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 5. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH.
    Hemoglobin; 2006 Apr 10; 30(2):257-62. PubMed ID: 16798651
    [Abstract] [Full Text] [Related]

  • 6. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Apr 10; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 7. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center.
    Gamberini MR, Fortini M, De Sanctis V, Gilli G, Testa MR.
    Pediatr Endocrinol Rev; 2004 Dec 10; 2 Suppl 2():285-91. PubMed ID: 16462713
    [Abstract] [Full Text] [Related]

  • 8. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
    Br J Haematol; 2010 Feb 10; 148(3):466-75. PubMed ID: 19912219
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
    Voskaridou E, Christoulas D, Terpos E.
    Br J Haematol; 2011 Sep 10; 154(5):654-6. PubMed ID: 21615376
    [No Abstract] [Full Text] [Related]

  • 11. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun 10; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 12. Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major.
    Gomber S, Dabas A, Bagmar S, Madhu SV.
    J Pediatr Hematol Oncol; 2018 Jan 10; 40(1):56-59. PubMed ID: 29200160
    [Abstract] [Full Text] [Related]

  • 13. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.
    Ann Hematol; 2008 Jul 10; 87(7):545-50. PubMed ID: 18351337
    [Abstract] [Full Text] [Related]

  • 14. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF, Peng CT, Wu KH, Tsai CH.
    Hemoglobin; 2006 Jul 10; 30(2):215-8. PubMed ID: 16798646
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores.
    Kolnagou A, Kontoghiorghes GJ.
    Br J Haematol; 2010 Aug 10; 150(4):489-90; author reply 491. PubMed ID: 20507309
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.